VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35-0.09%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · VNRX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.3% |
| Our one-year growth estimate | diamond | 40.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 110.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
VNRX — capital allocation
Dated 2026-09-01
Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management XII LLC, a Delaware limited liability company (“Lind”), senior secured convertible promissory notes in the original principal amounts of $7,500,000 and $2,400,000. In connection with its obligations under such notes, (a) on Augu…
Why it matters: A publication could bring in a $5 million payment. It could also grow the Nu.Q Vet market.
Supportive ifThe study is published in a peer-reviewed journal.
Worry ifThe study is not published by the end of the year.
Why it matters: New deals would show that management wants to grow revenue. This would back their plan.
Supportive ifLook for news about a new deal with a big diagnostic company.
Worry ifNo new licensing agreements announced in the next quarter.
Why it matters: This offering could give needed money for operations and growth.
Watch forThe company uses money from the offering to support growth plans.
Also watch forThe company has trouble using the funds well or faces money issues.
Why it matters: Earnings results will show if revenue growth continues and if losses are managed.
Watch forQ2 revenue grows year over year by more than 50% from Q1.
Also watch forQ2 revenue does not grow or declines year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$491 on $10,000 · ±4.9% | How much price usually moves either way. |
| Bad day | $1,012 loss on $10,000 · 10.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,751 loss on $10,000 · 97.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Fixing compliance issues is key. It helps keep listing standards and investor trust.
Worry ifManagement has a clear plan and timeline to fix compliance issues.
Less concerning ifNo updates on compliance issues may lead to delisting.
Why it matters: New agreements could bring big payments and steady income for Volition.
Supportive ifVolition has a new licensing deal with a big diagnostic company.
Worry ifNo new agreements are announced, and talks with potential partners stall.
Why it matters: Regaining compliance is key. It helps avoid delisting and keeps investor trust.
Worry ifThe company has stockholders' equity of more than $2 million.
Less concerning ifNo growth in stockholders' equity or failure to meet compliance goals.
Why it matters: Getting reimbursement could help with regular use in clinics. This would increase revenue.
Supportive ifLook for news that the reimbursement submission is done.
Worry ifNo update on reimbursement submission by the end of the year.
Why it matters: Continued revenue growth signals success in strategic partnerships. This is key for future growth.
Supportive ifQ2 revenue growth is over $1 million. This shows strong partnerships.
Worry ifQ2 revenue is below $900,000. This shows problems with partnerships.
Why it matters: Regaining compliance is important. It helps keep the company's listing and boosts investor confidence.
Watch forManagement shares a clear plan with goals. They aim to regain compliance by August 2027.
Also watch forThe company does not meet compliance rules or gives no updates on progress.
Why it matters: The earnings report will show revenue growth. It will also show how operations are doing.
Watch forThe earnings report shows revenue growth over $1 million. This means there is strong demand.
Also watch forEarnings report shows revenue below $1 million, raising concerns about growth.
Why it matters: New partnerships can help grow revenue. They also support the company's strategy.
Supportive ifA new partnership is announced. It is expected to bring in over $1 million.
Worry ifNo new partnerships have been announced. This shows a slowdown in growth.
Why it matters: New agreements could bring in more money. They also support the business model.
Supportive ifThere is a new licensing agreement. It includes upfront payments or milestones.
Worry ifNo new agreements have been announced. Existing talks are not moving forward.